The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.
about
Advances in targeting signal transduction pathwaysPAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesisGroup I PAK inhibitor IPA-3 induces cell death and affects cell adhesivity to fibronectin in human hematopoietic cellsBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsDevelopment of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.Republished: tracing PAKs from GI inflammation to cancerPrognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesisProtein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.MicroRNA analysis suggests an additional level of feedback regulation in the NF-κB signaling cascadeThe AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapyMitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.Tracing PAKs from GI inflammation to cancer.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Structure, biochemistry, and biology of PAK kinases.An RNA interference screen identifies new avenues for nephroprotection.ETV1 positively regulates transcription of tumor suppressor ARF.P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
P2860
Q27686983-DFD063D4-5145-4992-8CDC-2EEE37740263Q28260745-4D79BCA4-CD4C-45B0-9399-D7A442B92121Q28541395-ED4CB2CE-33D6-4523-8812-361AD868CBFFQ28543370-0C57203C-68AE-4DB5-A887-815ECAF73A83Q34346905-EFF1448A-70C7-4A98-B2D6-3474BD139C5EQ34463139-EAEB8571-B6AE-437F-8558-DCBE3929C393Q35043996-E8084339-6775-4652-B4E6-E36656579E5BQ35625798-24BFD8ED-E571-45E2-BCD8-F09E3F818145Q36188433-9DB007DE-BCBB-4418-9B1C-7294C882C3F2Q36231978-B9C82EB6-A249-4CFE-8BBD-98F120A1A6A1Q37299276-79128568-0721-4662-9865-6FF5A0D868E7Q37420174-77C5C4B9-3C51-437F-AA2E-DFF9B9D07DAAQ38210506-51B3B138-2012-4C96-A1AA-AF514F771479Q38722990-36F6C7B3-095E-442A-85D5-0B327D2D2BB4Q38779105-333EA7EF-73E5-4142-B714-66B739D01003Q38819738-C59B9DFE-BC50-420A-B840-D1AF099EDBBDQ39071032-FA3D2685-3F4C-469E-9E32-10D01163D485Q39174795-2D805487-9931-4D80-9D58-ABE6A99A0822
P2860
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@en
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@nl
type
label
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@en
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@nl
prefLabel
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@en
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@nl
P2860
P356
P1433
P1476
The response to PAK1 inhibitor ...... ons in BRAF and Ras oncogenes.
@en
P2093
Eugene S Kandel
Ruchi Singhal
P2860
P304
P356
10.18632/ONCOTARGET.587
P407
P577
2012-07-01T00:00:00Z